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Abstract
Background: Some forms of pharmacotherapy are shown to increase the risk of community-acquired pneumonia 
(CAP). The purpose of this study is to investigate whether pharmacotherapy with proton pump inhibitors (PPI), inhaled 
corticosteroids, and atypical antipsychotics was associated with the increased risk for CAP in hospitalized older adults 
with the adjustment of known risk factors (such as smoking status and serum albumin levels).
Methods: A retrospective case-control study of adults aged 65 years or older at a rural community hospital during 
2004 and 2006 was conducted. Cases (N = 194) were those with radiographic evidence of pneumonia on admission. 
The controls were patients without the discharge diagnosis of pneumonia or acute exacerbation of chronic obstructive 
pulmonary disease (COPD) (N = 952). Patients with gastric tube feeding, ventilator support, requiring hemodialysis, 
metastatic diseases or active lung cancers were excluded.
Results: Multiple logistic regression analysis revealed that the current use of inhaled corticosteroids (adjusted odds 
ratio [AOR] = 2.89, 95% confidence interval [CI] = 1.56-5.35) and atypical antipsychotics (AOR = 2.26, 95% CI = 1.23-4.15) 
was an independent risk factor for CAP after adjusting for confounders, including age, serum albumin levels, sex, 
smoking status, a history of congestive heart failure, coronary artery disease, and COPD, the current use of PPI, β2 
agonist and anticholinergic bronchodilators, antibiotic(s), iron supplement, narcotics, and non-steroidal anti-
inflammatory drugs. The crude OR and the AOR of PPI use for CAP was 1.41 [95% CI = 1.03 - 1.93] and 1.18 [95% CI = 
0.80 - 1.74] after adjusting for the above confounders, respectively. Lower serum albumin levels independently 
increased the risk of CAP 1.89- fold by decreasing a gram per deciliter (AOR = 2.89, 95% CI = 2.01 - 4.16).
Conclusion: Our study reaffirmed that the use of inhaled corticosteroids and atypical antipsychotics was both 
associated with an increased risk for CAP in hospitalized older adults of a rural community. No association was found 
between current PPI use and the risk for CAP in this patient population of our study.
Background
Community-acquired pneumonia (CAP) is one of the
m a j o r  l e a d i n g  c a u s e s  o f  d e a t h  i n  o l d e r  a d u l ts  [ 1 , 2 ] .  I n
2006, adults aged 65 years or older accounted for approx-
imately 57% of the total number of pneumonia discharges
from hospitals in the US [3].
Identifying risk factors and implementing strategies in
reducing the exposure to modifiable conditions may
decrease mortality and morbidity. Risk factors that are
associated with CAP include age [4,5], chronic obstruc-
tive pulmonary disease (COPD) [5], asthma, diabetes
mellitus, congestive heart failure [4-6], smoking [4-9],
malnutrition [10-13], and aspiration. More studies reveal
that some forms of pharmacotherapy may increase the
risk of CAP. Current use of atypical antipsychotic drugs is
shown to increase the risk of pneumonia in the elderly
patients by 2.1 folds in a nested case-control study [14].
The use of proton pump inhibitors (PPI) significantly
increases the risk of CAP by 50% to 89% [15-17] and hos-
pital-acquired pneumonia by 30% [18], particularly in
those patients with a recent initiation of PPI therapy
[15,16,19]. However, a conflicting result was reported
with the use of long-term PPI therapy in a study of
approximately 880,000 patients by using the UK General
Practice Research Database [19]. Subsequently, a meta-
analysis study of clinical trials failed to show a definite
conclusion [20]. While COPD is increasingly common in
older adults, the use of inhaled corticosteroids is shown
* Correspondence: gau@oucom.ohiou.edu
1 Department of Geriatric Medicine/Gerontology, Ohio University College of 
Osteopathic Medicine (OU-COM), Athens, OH 45701, USA
Full list of author information is available at the end of the articleGau et al. BMC Geriatrics 2010, 10:45
http://www.biomedcentral.com/1471-2318/10/45
Page 2 of 8
to significantly increase the risk of pneumonia by 34% as
shown by a meta-analysis study (ranges of odds ratio:
0.67-3.16 among the studies cited) [21-25].
Malnutrition contributes to the increasing risks for
CAP as demonstrated by several studies [10-13]. Results
of previous pharmacotherapy studies that demonstrated
the increased risk for CAP were mainly from large data
bases, and there was no adjustment for nutritional status
among those studies. Because older adults often suffer
from malnutrition and therefore, are susceptible to CAP,
it is important to include nutritional status in analyzing
the association between risk factors and CAP in this age
population.
The purpose of this study is to investigate whether the
association between pharmacotherapy with PPI, inhaled
corticosteroids, and atypical antipsychotics and the
increased risk for CAP also holds true among hospital-
ized older adults of a rural community with the consider-
ation of known risk factors (such as smoking status and
serum albumin levels).
Methods
Setting
Data were retrieved from 2004 and 2006 medical records
of a community hospital by trained research assistants.
Medical records from 2005 were not available during the
study period (being sent out for microfilm storage). All
data were recorded on standardized paper forms and all
medical records under study were reviewed and verified
by the principal investigator for accuracy. This hospital is
the major one in the Athens county community of the
State of Ohio that provides 62,000 residents first-line
access to an emergency department (ED) and/or hospital-
izations. This study was approved by the Ohio University
Institutional Review Board.
Identification and ascertainment of cases and control 
subjects
Adults aged 65 years or older who were hospitalized dur-
ing 2004 and 2006 were identified by the assistance of
medical record department staff. Patients with the fol-
lowing diagnosis or conditions were excluded from our
study: clinically-evident aspiration pneumonia or pneu-
monitis (N = 47) due to documented dysphagia or with
gastro-duodenal tube feeding (N = 7) as patients with
aspiration pneumonia differ from CAP in the pathophysi-
ology and risk factors [19]; documented known active
lung cancer or metastatic disease (including leukemia; N
= 32) as they have underlying conditions that predispose
to airway obstruction and pneumonia; being on ventila-
tor therapy (N = 14) as they have a high risk for ventila-
tor-associated and nosocomial pneumonia; death during
hospital stay; requiring hemodialysis as those patients
were transferred to tertiary care centers; and others
(incomplete records or charts not available for review [n
= 25]; patients who could not recall medication use [n =
3]).
Cases of CAP were identified initially by the discharge
diagnosis and further confirmed by the report of the
radiographic findings (a new infiltrate or consolidation)
suggestive of pneumonia. Patients with "atypical" clinical
presentation (such as mental status changes, increasing
lethargy, or accidental falls without the classic symptoms
such as productive cough, dyspnea, or fever; N = 17) were
included in the final data analysis. Hospital-acquired
pneumonia (N = 5) were not included in our study.
Patients from nursing homes with pneumonia were
included in our data analysis. Only the medical records of
the first occurrence of hospitalizations with pneumonia
episode during that year were reviewed. Total 194 cases
were identified and included in the final data analysis.
The control group was selected as follows: all hospital-
ized patients aged 65 or older were initially identified by
all diagnostic codes (from 0 to 9999). After excluding
those with the primary discharge diagnosis of pneumo-
nia, acute and chronic respiratory failure on ventilator
therapy, and the conditions previously mentioned in the
case group (i.e., death during hospital stay, active lung
cancers or metastatic cancers), the first admission medi-
cal record was reviewed and data were recorded. Because
acute exacerbation of chronic obstructive pulmonary dis-
ease (AECOPD) may overlap with pneumonia in clinical
presentation, patients with the discharge diagnosis of
AECOPD (N = 111) were excluded from both the case
and the control groups.
All cases were reviewed by the principal investigator
and further efforts were made (based on the documented
x-ray findings on admission) to classify each case into an
appropriate category (cases vs. controls). The approxi-
mate 1:5 ratio of the cases to the controls was not inten-
tional but co-incident. A total of 952 patients were
included in the control group.
Measurement
Age, sex, demographic data, smoking status, past medical
history, medication use prior to admission, admission
and discharge diagnosis, admission laboratory test results
(i.e., white cell count, serum albumin level, and electro-
lytes) obtained at ED or the first set of blood tests on
admission were recorded. Medication use prior to admis-
sion was based on the documentation on the medication
reconciliation forms or physician's notes (current use vs.
non-use). Nursing home residents almost had medication
administration records available for review.
PPI is the group of medications that include omepra-
zole, lansoprazole, pantoprzaole, rabeprazole and esome-
prazole. β2 agonist bronchodilator is the group of
inhalation medications of short or long-acting effects.Gau et al. BMC Geriatrics 2010, 10:45
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Atypical antipsychotic drugs include clozapine, olanzap-
ine, quetiapine, aripiprazole, ziprasidone, and risperi-
done. Because very few study patients used typical
antipsychotic drugs prior to admission, such category of
medication was not reported. Systemic corticosteroids
were not included in the data analysis as very few patients
received such a treatment in our study. Further informa-
tion on the duration of medication use was not available.
Smoking status was based on the documented ex-
smoker vs. current smoker from physicians' notes. Co-
morbidity (such as congestive heart failure, coronary
artery disease, diabetes, COPD, prior pneumonia, and
atrial fibrillation), which is common in the elderly , was
the documented previous event or existing condition
prior to the study period, and it was recorded as ever vs.
never event.
Missing data were encountered in the smoking history
and laboratory results. Patients without documented data
were excluded from the data analysis.
Data analysis
Mean, standard deviation (SD), and percentage with fre-
quency were used to report continuous and discrete vari-
ables. Chi-square test and two-sample t-tests (two-sided)
were used to assess if there was a significant association
between two groups. Multiple logistic regression with
odds ratio (OR) with a 95% confidence interval (CI) was
used to measure the association between a risk factor and
the occurrence of CAP after adjusting for other variables
in the model.
Potential confounders used in the multiple logistic
regression model analysis included age, serum albumin
levels (gram per deciliter), sex, smoking status (ex- and
current smoker), a past medical history of congestive
heart failure, coronary artery disease, and COPD, and the
use of the following medications: atypical antipsychotic
drugs, β2 agonist and anticholinergic bronchodilators,
inhaled corticosteroids, and prescribed antibiotic(s) prior
to admission, iron supplement, narcotics, and non-steroi-
dal anti-inflammatory drugs (NSAIDs). A history of
COPD and medication used for the treatment of COPD
were both included in the adjustment in order to analyze
whether the treatment is an independent risk factor for
CAP in addition to the presence of disease.
Regression diagnostics showed no colinearity among
the risk factors and no noticeable outlier or influential
observations in the model. Hosmer and Lemeshow good-
ness-of-fit test was used to assess the fit of the model to
data. Statistical significance level was set at a level of .05.
Statistical software package, PC SAS version 9.1 (SAS
Institute, Inc., Cary, NC) was used to perform the statisti-
cal analyses.
Results
As shown in Table 1, case patients had a significantly dif-
ferent clinical profile compared to the control group.
Case patients were more likely to be ex- or current smok-
ers and had a significant medical history of congestive
heart failure, coronary artery disease, pneumonia and
COPD than the controls. Case patients were more likely
to receive atypical antipsychotic drugs, PPI, β2 agonist
and anticholinergic bronchodilators, inhaled corticoster-
oids, prescribed antibiotic(s) prior to admission, narcot-
ics and iron supplements (all p values < 0.05). On the
admission blood test results, the case group had a signifi-
cantly lower mean serum albumin level (2.9 ± 0.5 vs. 3.2 ±
0.5 gm/dL, p < 0.001) and a higher mean white blood cell
count (13.6 ± 6.0 vs. 9.3 ± 4.0 K/μL, p < 0.001) than the
control group.
Discharge diagnoses among study patients were shown
in Additional file 1 and Table 1. There was no difference
in the proportions of upper and lower gastro-intestinal
(GI) illness, and hepato-biliary-pancreatic diseases
between PPI users and non-users (except in the pneumo-
nia diagnosis). While acute congestive heart failure was
more often seen in the case group, GI-related diagnoses
were more common in the controls (Table 1).
As shown in Table 2, lower serum albumin level, ex-
and current smoker, a history of congestive heart failure
and COPD, and the use of atypical antipsychotic drugs
(adjusted OR = 2.26, 95% CI = 1.23 - 4.15), inhaled corti-
costeroids (adjusted OR = 2.89, 95% CI = 1.56 - 5.35), and
prescribed antibiotic(s) prior to admission (adjusted OR
= 1.81, 95% CI = 1.09 - 3.02) was significantly associated
with an increased risk for CAP after adjusting for the
potential confounders as listed in the table 2. The unad-
justed OR of PPI exposure for CAP was 1.41 with 95% CI
= 1.03 - 1.93; the association became weaker and not sig-
nificant after adjusting for all other confounders
(adjusted OR = 1.18, 95% CI = 0.80 - 1.74). Our study
revealed that lower serum albumin levels independently
increased the risk of CAP by 189% by decreasing the con-
centration of one gram per deciliter (AOR = 2.89, 95% CI
= 2.01 - 4.16).
Discussion
This case-control study reaffirmed that the use of inhaled
corticosteroids and atypical antipsychotic drugs was
independently associated with an increased risk for CAP
among hospitalized older adults of a rural community
with the adjustment of nutritional status based on serum
albumin levels and other risk factors. However, the asso-
ciation between current PPI exposure and the risk for
CAP was not observed in our study. Our study also dem-
onstrated that by decreasing serum albumin level by oneGau et al. BMC Geriatrics 2010, 10:45
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gram per deciliter, the risk for CAP can be increased by
1.89- fold in older adults.
COPD has been demonstrated as a major risk factor for
CAP. Inhaled corticosteroids, often prescribed for the
treatments of COPD and/or asthma, were also identified
as an independent risk factor by our study and others [20-
24]. Although inhaled corticosteroid therapy may
improve the quality of life [26], inappropriate prescrip-
tions of these medications may be highly prevalent
among stable COPD patients [27]. Re-evaluating the need
for a long-term corticosteroid therapy or using it at a
minimally effective dose is warranted.
Our study also demonstrated that atypical antipsy-
chotic drug use independently increased the risk of CAP,
which was consistent with the report by Knol et al [14].
Their study included all types of pneumonia in the cases
and demonstrated a 2.1-fold increase in the risk for CAP
among those taking atypical antipsychotic drugs. With
the exclusion of aspiration pneumonia in the case group,
our study still revealed a similar result with a modest risk
(AOR = 2.26, 95% CI = 1.23-4.15). Effects of atypical
antipsychotic drugs on the gastrointestinal system and
particularly on the esophageal dysfunction were
described [28]. Though it is highly possible that the
intrinsically sedative and anticholinergic side effects of
this group medication could increase the risk of aspira-
tions by decreasing peristalsis, the exact mechanism of
increasing the risk for CAP is not clear.
Our study did not find an association between current
PPI therapy and the risk for CAP after the adjustment for
confounders. The result was consistent with a recent
Table 1: Characteristics of Cases with Community-Acquired 
Pneumonia and Control Subjects
Variables*
N (%)
Cases
N = 194
Control
N = 952
P value§
Mean age (yr) (SD) 80.3 (8.5) 79.8 (8.1) .486
Female 119 (61) 641 (67) .108
White 194 (100) 941 (98.8) .133
Ex-smoker† 60/191 (31) 151/949 (16) < .001
Current smoker† 28/191 (15) 73/949 (8) .002
Past Medical History
Congestive heart 
failure
63 (32) 201 (21) < .001
Coronary artery 
disease
77 (40) 299 (31) .025
COPD 91 (47) 178 (19) < .001
Prior pneumonia 38 (20) 43 (5) < .001
Diabetes mellitus 52 (27) 277 (29) .520
Atrial fibrillation 35 (18) 136 (14) .181
Stroke 34 (18) 148 (16) .492
Cognitive impairment 40 (21) 152 (16) .114
Depression 58 (30) 243 (26) .207
Psychiatric illness 7 (4) 24 (3) .395
GERD 56 (29) 233 (24) .199
Medication
Atypical 
antipsychotics
25 (13) 63 (7) .003
Proton pump inhibitor 86 (44) 343 (36) .030
H2 receptor antagonist 7 (4) 46 (5) .460
Antihistamine 29 (15) 129 (14) .607
β2 agonist
bronchodilator
72 (37) 109 (11) < .001
Inhaled corticosteroid 49 (25) 47 (5) < .001
Anticholinergic
bronchodilator
44 (23) 63 (7) < .001
Antibiotic use prior to
admission
44 (23) 88 (9) < .001
NSAIDs 27 (14) 115 (12) .479
Narcotics 60 (31) 224 (24) .030
Iron supplement 37 (19) 82 (9) < .001
Admission laboratory 
results
Serum albumin (gm/dL) 2.9 (0.5)
(N = 167)
3.2 (0.5)
(N = 807)
< .001
White cell count (K/μL) 13.6 (6.0)
(N = 194)
9.3 (4.0)
(N = 949)
< .001
Serum potassium
(mmol/L)
4.1 (0.6)
(N = 194)
4.1 (0.7)
(N = 948)
.631
Discharge diagnoses
Congestive heart 
failure
46 (24) 107 (11) < .001
Any GI-related illness 18 (9) 269 (28) < .001
Upper GI illness‡ 8 (4) 100 (11) .006
Lower GI illness¶ 10 (5) 140 (15) < .001
C. difficile associated
Diarrhea
7 (4) 27 (3) .564
* Data were presented by number (percent) or mean (SD).
† Smoking status was unknown in 3 patients of cases and in 3 
patients of controls.
‡ Including esophageal, stomach, duodenum, and small intestine 
diagnoses.
¶ Including large colon and rectal diagnoses, but not C. difficile 
associated diarrhea.
§ Obtained using chi-square or two-sample-t test.
Abbreviations: SD = standard deviation; C. difficile = Clostridium 
difficile; COPD = chronic obstructive pulmonary disease; GERD = 
gastro-esophageal reflux disease; GI = gastro-intestinal; NSAIDs = 
non-steroidal anti-inflammatory drugs.
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Table 2: Odds Ratio for the Risk Factors Associated with Community-Acquired Pneumonia in the Multiple Logistic 
Regression Model* (N = 969)
Variables† Cases
(Yes/No)‡
Control (Yes/No)‡ Crude OR
[95% CI]
Adjusted OR
[95% CI]
Age (yr) -- -- 1.01
[0.99-1.03]
1.01
[0.99 - 1.04]
Number of serum albumin level below 4 gm/deciliter¶ -- -- 3.23
[2.34 - 4.47]
2.89
[2.01 - 4.16]
Sex (female = 1/male = 0) 119/75 641/311 0.77
[0.56 - 1.06]
1.01
[0.66 - 1.53]
Ex-smoker 60/131 151/797 2.42
[1.70 - 3.44]
1.88
[1.15 - 3.06]
Current smoker 28/163 73/876 2.06
[1.29 - 3.29]
2.34
[1.22 - 4.50]
Past Medical History
Congestive heart failure 63/131 201/751 1.80
[1.28 - 2.52]
1.60
[1.04 - 2.46]
Coronary artery disease 77/117 299/653 1.44
[1.05 - 1.98]
1.40
[0.94 - 2.08]
COPD 91/103 178/774 3.84
[2.77 - 5.32]
1.82
[1.17 - 2.82]
Medication
Atypical antipsychotics 25/169 63/889 2.09
[1.28 - 3.41]
2.26
[1.23 - 4.15]
Proton pump Inhibitor 86/108 343/609 1.41
[1.03 - 1.93]
1.18
[0.80 - 1.74]
β2 agonist
bronchodilator
72/122 109/843 4.56
[3.21 - 6.50]
1.29
[0.69 - 2.40]
Anticholinergic bronchodilator 44/150 63/889 4.14
[2.71 - 6.31]
1.16
[0.59 - 2.26]
Inhaled corticosteroid 49/145 47/905 6.51
[4.20 - 10.07]
2.89
[1.56 - 5.35]
Antibiotic use prior to admission 44/150 88/864 2.88
[1.93 - 4.30]
1.81
[1.09 - 3.02]
Iron supplement 37/157 82/870 2.50
[1.64 - 3.82]
1.58
[0.94 - 2.67]
Narcotics 60/134 224/728 1.46
[1.04 - 2.04]
1.01
[0.66 - 1.56]
NSAIDs 27/167 115/837 1.18
[0.75 - 1.85]
1.25
[0.70 - 2.23]
* Hosmer and Lemeshow goodness-of-fit test: chi square = 16.43, df = 8, p = .037.
† Variables were dichotomized as 1 = yes, 0 = no, unless stated otherwise.
‡ indicated the number of the presence (yes) and the absence (no) of the medical condition or exposed (yes) vs. unexposed (no) to 
medication use for the variable of interest.
¶ Which is equal to the number of 4 minus patient's serum level.
Abbreviations: CI = confidence interval; COPD = chronic obstructive pulmonary disease; NSAIDs = non-steroidal anti-inflammatory drugs; OR 
= odds ratio.
report of a large nested, case-control study by using the
UK General Practice Research Database by Sarkar et al.
[19], in which patients with the diagnosis of aspiration
pneumonia were excluded in the data analysis as we did
in our study. Please note that the study by Sarkar et al.
included cancers in the full adjustment when reporting
the adjusted OR, while our study excluded active lung
cancers and metastatic diseases in the final data analysis.
Compared to previous studies that reported the associa-
tion between PPI use and the risk for CAP (but not hospi-Gau et al. BMC Geriatrics 2010, 10:45
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tal-acquired pneumonia) [15-17], the exclusion of
aspiration pneumonia was not explicitly mentioned in
their studies, which could be one of the possible explana-
tions for the discrepancy of reported findings between
ours and other studies.
Our studied patients had a higher prevalence rate of co-
morbidities, and a higher percentage of patients received
PPI therapy compared to other studies [15-17]. This find-
ing was expected as aging older adults have more co-
morbidity and increasingly use pharmacotherapy for
chronic illness, especially among hospitalized patients.
As the most potent acid-suppression drugs, PPIs have
substantially replaced H2 receptor antagonists for the
treatment of acid-related gastroesophageal diseases. Evi-
dence suggests that patients with multiple co-morbid
conditions are most likely to receive PPI therapy [29], and
it is also this group of patients who are most vulnerable to
lower respiratory tract infections. Evidence also suggests
that hypoalbuminemia and malnutrition are associated
with CAP in older adults [10-12], which is also demon-
strated by our study. However, PPI users and non-users
had no difference in average serum albumin levels among
hospitalized older patients as demonstrated in our previ-
ous study [30].
Despite PPI therapy drastically reduces gastric acid
secretion it does not prevent or inhibit the gastro-esoph-
ageal reflux episodes. Clinical observations suggest that
reflux of gastric contents into the upper and lower airway
may precipitate acute asthma attacks, or acute exacerba-
tion of COPD though there is no strong evidence from
clinical studies [31,32]. It is quite possible that PPI ther-
apy could also be prescribed for the early symptoms that
are associated with lower respiratory tract infections or
gastro-esophageal reflux disease (GERD) (i.e., proto-
pathic bias). This may partially explain why PPI therapy
started within the past 7 to 14 days of pneumonia diagno-
sis was found to be associated with an increased risk for
pneumonia in some studies [15,16,19].
Another possible explanation for the different result
observed between our and other studies [15,16] was the
categorization of exposure history. Other studies [15,16]
had data available (based on prescriptions of PPIs) that
employed three categories: current, recent, and past use;
ours only included current use vs. non-use. Furthermore,
our study was hospital-based, case-control. One may sug-
gest that a Berkson's bias, a phenomenon in which the
relationship between exposure and disease becomes
indistinct in hospital-based studies, may occur in our
study. Although we could not exclude the possibility, this
current study also demonstrated the association between
the use of inhaled corticosteroids and atypical antipsy-
chotic drugs and the increased risk for CAP in our stud-
ied patients. Because of the small sample size compared
to those population-based studies, the issue of statistical
power could be one of the explanations for the lack of the
association. However, other investigators [19] of a large
study also reported a finding similar to ours in the rela-
tionship between overall PPI use and the risk for CAP.
Therefore, we do not believe that increasing the sample
size will change the conclusions drawn from our study.
Whether age could be an explanation for the discrep-
ancy between our study and the others [15-17] is an inter-
esting question. In the study by Gulmez et al. [16], the
association between current use of PPI and CAP became
weaker in the age group of older than 60 years (adjusted
OR 1.5, 95% CI = 1.3 - 1.7) when compared to the age
group of less than 40 years (adjusted OR 2.3, 95% CI = 1.3
- 4.0). We speculate that the association between PPI use
and the risk for CAP may become non-significant in the
advanced aged group. As demonstrated by Sarkar et al.
[19], their paper also reported no association between
PPI use and the risk for CAP in persons aged 60 years or
older.
As gastric acid production decreases with aging and
there is a high prevalence rate of chronic gastritis in peo-
ple aged older than 70 years, there may be a high preva-
lence rate of bacterial colonization in the upper gastro-
esophageal tract of older adults at baseline even in those
older people not receiving PPI therapy. If this is true, use
of PPI therapy may not further increase the prevalence
rate of bacterial colonization in older adults, by which is
the mechanism thought to be responsible for the
increased risk for CAP by PPI therapy. There is no infor-
mation in how PPI therapy affecting the rate of bacterial
colonization in older adults compared to young adults in
the literature.
One of the strengths in our study was to demonstrate
that patients with CAP had a significantly higher mean
white blood cell count on admission compared to the
control patients (Table 1). Though we could not exclude
the possible use of systemic corticosteroid treatment
prior to the blood tests obtained in the ED or on admis-
sion as the cause of leukocytosis, the exclusion of acute
exacerbation of COPD, respiratory failure requiring a
ventilator therapy and leukemia cases from our data anal-
ysis, as well as very few patients receiving oral systemic
steroid therapy, should minimize such a possibility. Our
study also demonstrated that lower serum albumin levels
independently increased the risk for CAP 1.89-fold in
older adults. This is the first of such a report to the best of
our knowledge.
The limitations of our study included the lack of diver-
sity as the study subjects were a predominately white
population. Therefore, the findings may not apply to
other ethnic groups. Furthermore, our data collection
resources could not confirm whether patients were com-
pliant with medication use nor the duration as the data
collection was based on medical records and physician'sGau et al. BMC Geriatrics 2010, 10:45
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notes. Dosage information will provide more insights into
the association between a drug therapy and the risk for
CAP. Another limitation was unmeasured or residual
confounding. Examples are the use of NSAIDs, as readily
available over-the-counter, and co-morbidity that may
not be completely documented by health-care providers.
Certain medical conditions that may be under- assessed
and under-documented, such as cognitive impairment or
dementia, lack of standardized criteria for making a diag-
nosis of diseases, as well as the lack of data on cognitive
functions prior to and during hospital stay, in which
potential limitations are all inherent to a retrospective
study design.
Conclusion
This case-control study of a rural community reaffirmed
that the use of inhaled corticosteroids and atypical antip-
sychotic drugs was an independent risk factor for CAP in
hospitalized older adults after adjusting for known risk
factors, including serum albumin levels. Current PPI use
did not increase the risk for CAP in this hospitalized
older population. Our study may imply that other fac-
tor(s), such as malnutrition or other pharmacotherapy,
may play a greater role than PPI therapy in developing
CAP in this population.
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